$-0.13 EPS Expected for VIVUS, Inc. (VVUS)
March 1, 2018 – By Jan Rainey
Investors sentiment decreased to 0.53 in 2017 Q3. Its down 0.74, from 1.27 in 2017Q2. It is negative, as 12 investors sold VIVUS, Inc. shares while 22 reduced holdings. 5 funds opened positions while 13 raised stakes. 32.65 million shares or 13.20% less from 37.61 million shares in 2017Q2 were reported.
The New York-based Blackrock has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). 15,404 were reported by Two Sigma Securities Ltd Liability Com. Bridgeway Capital Mngmt reported 637,200 shares or 0.01% of all its holdings. Moreover, Price T Rowe Assoc Md has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 51,000 shares. Millennium Mngmt Limited Liability Co has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). The New York-based D E Shaw has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Art Advisors Lc stated it has 0% in VIVUS, Inc. (NASDAQ:VVUS). Connor Clark And Lunn Inv Mgmt reported 90,121 shares. Hanson Mcclain has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 250 shares. Wells Fargo And Com Mn stated it has 0% in VIVUS, Inc. (NASDAQ:VVUS). First Manhattan stated it has 0% of its portfolio in VIVUS, Inc. (NASDAQ:VVUS). Bank & Trust Of Montreal Can holds 0% or 110,000 shares in its portfolio. The Pennsylvania-based Sei Company has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Citadel Advsrs Limited Liability Corp holds 71,182 shares or 0% of its portfolio. Dekabank Deutsche Girozentrale reported 0% in VIVUS, Inc. (NASDAQ:VVUS).
Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.13 EPS on March, 14.They anticipate $0.67 EPS change or 124.07 % from last quarter’s $0.54 EPS. After having $-0.06 EPS previously, VIVUS, Inc.’s analysts see 116.67 % EPS growth. The stock decreased 3.88% or $0.0172 during the last trading session, reaching $0.4259. About 326,046 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 7.14% since March 1, 2017 and is downtrending. It has underperformed by 23.84% the S&P500.
VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage
Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. WallachBeth Capital upgraded VIVUS, Inc. (NASDAQ:VVUS) rating on Thursday, November 5. WallachBeth Capital has “Buy” rating and $2.80 target. The firm has “Outperform” rating given on Friday, July 31 by RBC Capital Markets. The rating was upgraded by Zacks to “Hold” on Wednesday, August 5.
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $45.13 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It has a 1.26 P/E ratio. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.